期刊文献+

大肠癌细胞表达的Fas配体具有功能性 被引量:1

Functional expression of Fas ligand in human colon cancer cells
下载PDF
导出
摘要 目的 :探讨大肠癌细胞 Fas配体 (Fas L ) m RNA和蛋白的表达及其功能。方法 :分别采用 RT- PCR和 Western印迹法以及氚释放细胞活性测定技术检测大肠癌细胞株中 Fas L m RNA和蛋白的表达及其功能。结果 :所检测的 6株大肠癌细胞(RPMI 4788、HCT- 116、DL D- 1、L o Vo、Wi Dr和 COL O 32 0 DM)全部表达 Fas L m RNA和蛋白 ;DL D- 1,L o Vo和 Wi Dr等部分大肠癌细胞具有 Fas依赖的细胞毒活性。其中 DL D- 1细胞活性具有量效关系 ,并且乙酸肉豆蔻佛波醇 (PMA )和离子霉素(ionom ycine )刺激能显著增强 DL D- 1的细胞活性。结论 :DL D- 1、L o Vo和 Wi Dr等 3株大肠癌细胞表达功能性 Fas配体 ,并可能以此反击机体免疫系统 ,逃避免疫监督。 Objective: To investigate the expression and function of Fas ligand (FasL) in human colon carcinoma cells. Methods: A total of 6 human colon cancer cell lines were examined for FasL mRNA and protein expression, Fas-dependent cytotoxicity and its modulation were detected by using RT-PCR, Western blot and 3H-TdR release assay. Results: FasL mRNA and protein was expressed in all of these 6 cancer cell lines RPMI 4788, HCT-116, DLD-1, LoVo, WiDr and COLO 320DM. Fas-dependent cytotoxicity to hFas transfectant was exerted in part of these cancer cells, such as DLD-1, LoVo and WiDr. The cytotoxicity was significantly enhanced by PMA and ionomycin. Conclusion: These data suggest that functional FasL is expressed, at least in part, in human colon cancer cell lines and may help to escape from immune surveillance of the host.
出处 《第二军医大学学报》 CAS CSCD 北大核心 2001年第9期803-805,共3页 Academic Journal of Second Military Medical University
基金 国家自然科学基金资助项目 ( 3990 0 14 3)
关键词 FAS配体 MRNA 大肠癌 PT-PCR Westem印迹法 氚释放细胞活性 Fas ligand RNA,messenger colonic neoplasms
  • 相关文献

参考文献1

  • 1Strand S,Nat Med,1996年,2卷,12期,1361页

同被引文献29

  • 1Webb SD, Sherratt JA, Fish RG. Cells behaving badly: a theoretical model for the Fas/FasL system in tumour immunology. Math Biosci 2002;179:113-129.
  • 2Andreola G, Rivoltini L, Castelli C, Huber V, Perego P, Deho P, Squarcina P, Accornero P, Lozupone F, Lugini L, Stringaro A, Molinari A, Arancia G, Gentile M, Parmiani G, Fais S.Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med 2002;195:1303-1316.
  • 3Li JH, Rosen D, Sondel P, Berke G. Immune privilege and FasL: two ways to inactivate effector cytotoxic T lymphocytes by FasL-expressing cells. Immunology 2002;105:267-277.
  • 4Koyama S, Koike N, Adachi S. Fas receptor counterattack against tumor-infiltrating lymphocytes in vivo as a mechanism of immune escape in gastric carcinoma. J Cancer Res Clin Oncol 2001;127:20-26.
  • 5Michael-Robinson JM, Pandeya N, Cummings MC, Walsh MD, Young JP, Leggett BA, Purdie DM, Jass JR, Radford-SmithG L. Fas ligand and tumour counter-attack in colorectal cancer stratified according to microsatellite instability status. J Pathol 2003;201:46-54.
  • 6rHouston A, Waldron-Lynch FD, Bennett MW, Roche D,O'Sullivan GC, Shanahan F, O'Connell J. Fas ligand expressed in colon cancer is not associated with increased apoptosis of tumor cells in vivo. Int J Cancer 2003;107:209-214.
  • 7Song E, Chen J, Ouyang N, Su F, Wang M, Heemann U. Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer. Br J Cancer 2001;85:1047-1054.
  • 8Oka S, Tanaka S, Hiyama T, Kitadai Y, Yoshihara M,Shimamoto F, Haruma K, Chayama K. Human telomerase reverse transcriptase, p53 and Ki-67 expression and apoptosis in colorectal serrated adenoma. Scand J Gastroenterol 2002;37:1194-1200.
  • 9Choi C, Benveniste EN. Fas ligand/Fas system in the brain: regulator of immune and apoptotic responses. Brain Res Brain Res Rev 2004;44:65-81.
  • 10Abrahams VM, Straszewski SL, Kamsteeg M, Hanczaruk B, Schwartz PE, Rutherford TJ, Mor G. Epithelial ovarian cancer cells secrete functional Fas ligand. Cancer Res 2003;63:5573-5581.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部